News

Oxeia Announces Positive Interim Results of Phase 2 Trial for OXE103 for the Treatment of Concussions
August 3, 2022
0
Genetic Engineering & Biotechnology News – Bitter Taste Receptors Represent a Therapeutic Sweet Spot
February 2, 2022
0
Aardvark Therapeutics, Inc., Announces the Initiation of Enrollment for Three Phase 2 Clinical Trials Of Oral ARD-101
February 2, 2022
0
Oxeia Biopharmaceuticals Announces New Board and Management Team Members and Relocates Corporate Headquarters To Boston
January 20, 2022
0
Swiss Gondola Medical Technologies Announces Collaboration with New York’s Mount Sinai Health System to Study Innovative Treatment for Neurological Disorders Such as Parkinson’s Disease
November 3, 2021
0